NIH Locks Down Blood and Tissue from Sneaky Foreign Spies
Published Date: 12/12/2025
Notice
Summary
The NIH now requires stronger security for human biospecimens funded by them to protect people and national safety. This affects researchers and labs handling these samples, with new rules effective since October 24, 2025. These changes help stop risky access by foreign countries and don’t add extra costs but do require careful handling.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
Applies to all NIH‑funded biospecimens
The policy applies to all human clinical and research biospecimens obtained from U.S. persons that are collected, obtained, stored, used, or distributed with any on-going or new NIH funding mechanism, regardless of NIH funding level. This rule became effective October 24, 2025 and covers biospecimens from U.S. persons whether or not they are identifiable.
Ban on sharing with countries of concern
Entities that hold NIH‑funded human biospecimens of U.S. persons are prohibited from directly or indirectly distributing those biospecimens to institutions or parties located in 'countries of concern' as determined under 28 CFR 202.601. The prohibition applies to biospecimen distribution unless one of the policy's limited exceptions is met.
Limited exceptions allow some transfers
Biospecimens may be shared with countries of concern only in limited circumstances: (1) transactions required or authorized by Federal law or international agreements (including global health) or necessary for compliance with Federal law; (2) rare and compelling cases where needed capability/expertise exists only in that country and the individual consented; or (3) at the request of the individual for their diagnosis, prevention, or treatment and in compliance with applicable Federal laws. Any such sharing must meet these specified conditions.
Documentation and retention requirement
NIH requires entities that share or distribute biospecimens to countries of concern under an allowable exception to retain documentation of those transactions, including the quantity and content of material shared, and to provide that documentation to NIH upon request. Entities must keep these records for any sharing done under the policy's limited circumstances.
Exemption for already public/commercial cell lines
The policy does not apply to cell derivative products or cell lines derived from human biospecimens of U.S. persons that were commercially or publicly available prior to the policy's effective date of October 24, 2025. However, cell lines that had agreements to be made commercially or publicly available but were not yet available on or after the effective date remain covered.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-11367 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting science projects. If you’re involved in cell biology, heart disease, mental health, or cancer research, these reviews could impact your funding timeline and opportunities.
2026-11357 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
2026-11018 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late June and early July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10813 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Previous / Next Documents
Previous: 2025-22617 — Foreign-Trade Zone (FTZ) 189, Notification of Proposed Production Activity; Plascore, Incorporated; (Metal, Aramid Paper and Plastic Honeycomb); Zeeland, Michigan
Plascore, Inc. in Zeeland, Michigan wants to start making special honeycomb and metal products using some imported materials under Foreign-Trade Zone rules. This change could help them save money and speed up production by handling certain parts more easily. The government is reviewing their plan, which was officially submitted on December 8, 2025.
Next: 2025-22619 — Biosimilar User Fee Act; Stakeholder Consultation Meetings on Biosimilar User Fee Act Reauthorization; Request for Notification of Stakeholder Intention To Participate
The FDA is inviting patients, consumer groups, and other stakeholders to join monthly meetings starting April 2026 to help shape the next Biosimilar User Fee Act, which expires in September 2027. These talks will guide how fees for biosimilar drug makers are collected in the future, ensuring everyone’s voice is heard. If you want in, let the FDA know by January 30, 2026!